The socio-economic burden of H1-antihistamine-refractory chronic spontaneous urticaria in Germany.

Autor: Augustin M; Universitätsklinikum Hamburg Eppendorf, IVDP, Hamburg, Germany., Beier D; InGef-Institut für angewandte Gesundheitsforschung Berlin, Berlin, Germany., Branner J; WifOR Institute Darmstadt, Darmstadt, Germany., Häckl D; WIG2 Wissenschaftliches Institut für Gesundheitsökonomie und Gesundheitssystemforschung Leipzig, Leipzig, Germany., Hampel R; GKM Therapieforschung München, München, Germany., Kramps T; Novartis Pharma GmbH, Nürnberg, Germany., Kurzen H; Haut-und Laserzentrum Freising, Freising, Germany., Lintener H; WifOR Institute Darmstadt, Darmstadt, Germany., Melzer N; Novartis Pharma GmbH, Nürnberg, Germany., Müller M; WifOR Institute Darmstadt, Darmstadt, Germany., Staubach P; Department of Dermatology, University Medical Center Mainz, Mainz, Germany., Schwichtenberg U; Derma-Nord Hautarztpraxis Bremen, Bremen, Germany., Termeer C; Practice, Stuttgart, Germany.; Department of Dermatology, University of Freiburg, Freiburg, Germany., Zink A; Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Fakultät für Medizin, Technische Universität München, Munich, Germany.; Division of Dermatology and Venereology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Nathan P; Novartis Pharma GmbH, Nürnberg, Germany., Maurer M; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
Jazyk: angličtina
Zdroj: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Nov; Vol. 38 (11), pp. 2102-2109. Date of Electronic Publication: 2024 May 11.
DOI: 10.1111/jdv.20071
Abstrakt: Background and Study Aim: Data from the AWARE study (A Worldwide Antihistamine-Refractory chronic urticaria patient Evaluation) illustrate a substantial disease burden in German patients with H1-antihistamine (-H1-AH)-refractory chronic spontaneous urticaria (CSU). Detrimental effects on patients' quality of life, poor disease control and impairment in the ability to work and perform other daily activities are reported. Based on these findings, this study aims to quantify the epidemiological and socio-economic burden of H1-AH-refractory CSU in Germany.
Methods: To determine the epidemiological burden of H1-AH-refractory CSU, the age- and gender-specific prevalence of CSU and the proportion of H1-AH-refractory patients in Germany anonymized data from the InGef research database have been used. In a second step, the socio-economic burden in terms of lost numbers of hours in paid and unpaid work was calculated by extrapolating the age- and gender-specific work productivity and activity impairment (WPAI) observed in AWARE to the H1-AH-refractory CSU population in Germany. Finally, productivity losses in paid and unpaid work were monetized using the human capital and the friction cost approach respectively. Moreover, socio-economic burden was calculated depending on symptom control of the patients (measured by urticaria control test [UCT]).
Results: In Germany, over 203,000 patients (20 years or older) had H1-AH-refractory CSU in 2018. The avoided lost paid and unpaid work hours attributable to H1-AH-refractory CSU summed up to over 100 million. Overall, the socio-economic burden of H1-AH-refractory CSU in monetary terms was evaluated at € 2.2 billion and the majority of this was due to unpaid work loss. Patients with poor disease control, as indicated by UCT score < 12, were more likely to suffer from high impairment than patients with controlled disease, resulting in a higher socio-economic burden.
Conclusions: The results of our analyses picture the substantial socio-economic burden of H1-AH-refractory CSU and therefore the tremendous impact it has on daily lives of individuals and society overall.
(© 2024 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)
Databáze: MEDLINE
Externí odkaz: